Abstract:Background: Percutaneous coronary interventions to implant bioresorbable vascular scaffolds (BVSs) were designed to reduce the late thrombotic events that occur with metallic stents.Purpose: To estimate the incidence of scaffold thrombosis after BVS implantation and compare everolimus-eluting BVSs with everolimus-eluting metallic stents (EESs) in terms of safety and efficacy at mid-and long-term follow-up in adults who had a percutaneous coronary intervention.Data Sources: PubMed, EMBASE, the Cochrane Library, conference proceedings, and relevant Web sites from inception until 20 May 2017, without language restriction.Study Selection: 7 randomized trials and 38 observational studies (each with a minimum of 6 months and 100 patient-years of follow-up) in adults with coronary artery disease who had a BVS or an EES and reported scaffold or stent thrombosis (main outcome) or other secondary outcomes (such as death, myocardial infarction, or revascularization).Data Extraction: 2 reviewers independently extracted study data, rated study quality, and assessed strength of evidence.Data Synthesis: The pooled incidence of definite or probable scaffold thrombosis after BVS implantation was 1.8% (95% CI, 1.5% to 2.2%) at a median follow-up of 1 year (41 studies, 21 884 patients) and 0.8% (CI, 0.5% to 1.3%) beyond 1 year (14 studies, 4688 patients). Seven trials involving 5578 patients that directly compared BVSs with EESs showed an increased risk for definite or probable scaffold thrombosis (odds ratio [OR], 3.40 [CI, 2.01 to 5.76]) with BVSs at a median follow-up of 25 months. Increased risks were present at early (prominently subacute), late, and very late stages, and odds beyond 1 year were almost double those seen within 1 year. Bioresorbably vascular scaffolds increased risks for myocardial infarction (OR, 1.63 [CI, 1.26 to 2.10]), target lesion revascularization (OR, 1.31 [CI, 1.03 to 1.67]), and target lesion failure (OR, 1.37 [CI, 1.12 to 1.66]); the odds for these 3 end points also increased over time. The incidences of all-cause, cardiac, and noncardiac death and of target vessel and any revascularization did not differ.Limitation: Quality of observational studies was unclear, and some data were unpublished.Conclusion: Compared with EESs, BVSs increased the risks for scaffold thrombosis and other thrombotic events at mid-and long-term follow-up, and risks increased over time.

Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review

Mid-to-long term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in coronary artery diseases: a meta-analysis of 7321 patients

The efficacy and safety of bioresorbable bascular scaffolds in percutaneous coronary intervention: a meta-analysis

Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Mid- And Long-Term Outcome Comparisons Of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents A Systematic Review And Meta-Analysis

Mid-term Outcomes of Bioresorbable Vascular Scaffolds Vs Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndromes

Efficacy and safety of bioresorbable scaffolds in patients with coronary bifurcation lesions: A systematic review and meta-analysis

Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials

Bioresorbable vascular scaffolds — basic concepts and clinical outcome

Follow-up of coronary artery patency after implantation of bioresorbable coronary scaffolds: The emerging role of magnetic coronary artery imaging

Bio-resorbable polymer stents: a review of material progress and prospects

Bioresorbable Scaffold: The Emerging Reality and Future Directions

Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice

Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis

Long-term outcomes following bioresorbable vascular scaffolds

Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China Trial.

Current perspectives on bioresorbable scaffolds in coronary intervention and other fields

Drug-eluting Bioresorbable Scaffolds in Cardiovascular Disease, Peripheral Artery and Gastrointestinal Fields: a Clinical Update

Thirty-Day and One-Year Clinical Outcomes of Bioresorbable Vascular Scaffold Implantation: A Single-Center Experience

Research Progress And Prospects Of Bioresorbable Vacular Scaffolds